Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
Haemonetics (HAE) Stock Price & Analysis
329 Followers
HAE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$70.74 - $95.26
Previous Close$84.17
Volume359.41K
Average Volume (3M)470.05K
Market Cap
$4.31B
Enterprise Value$4.99B
Total Cash (Recent Filing)$193.98M
Total Debt (Recent Filing)$870.59M
Price to Earnings (P/E)34.1
Beta0.75
Next Earnings
May 09, 2024EPS Estimate
$0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.46
Shares Outstanding50,786,117
10 Day Avg. Volume351,923
30 Day Avg. Volume470,047
Standard Deviation0.12
R-Squared0.03
Alpha0.00246
Financial Highlights & Ratios
Price to Book (P/B)-105.27
Price to Sales (P/S)13.73
Price to Cash Flow (P/CF)-1995.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.16
Enterprise Value/Gross Profit8.11
Enterprise Value/Ebitda24.88
Forecast
1Y Price Target
$105.75Price Target Upside24.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Haemonetics News
Bulls Say, Bears Say
Bulls Say
Financial GuidanceAnalyst confidence is signaled by the raised financial guidance for Haemonetics, anticipating higher reported revenue growth and adjusted EPS, which could attract investor interest in the company's upward trajectory.
Product DevelopmentWith the doubling of sales for Attune Medical's ensoETM device, Haemonetics is set to enhance its product portfolio within its Hospital business, reflecting a commitment to innovation and market expansion.
Revenue GrowthHaemonetics' acquisition of Attune Medical is expected to immediately contribute to the company's revenue growth and adjusted EPS, which is a strong positive for future financial performance.
Bears Say
Financial PerformanceOn a GAAP basis, it is expected to be slightly dilutive to EPS due largely to transaction and integration costs.
Market CompetitionRecently approved pulsed field ablation products are expected to take significant share from thermal ablation, where ensoETM is used.
Revenue ImpactRevenue associated with the anticipated winddown in the CSL relationship could provide somewhat of a headwind.
---
Ownership Overview
2.47% Insiders
45.80% Mutual Funds
24.12% Other Institutional Investors
27.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $70.74 and its highest was $95.26 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Currently, no data Available
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is May 09, 2024 which is in 21 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Feb 08, 2024. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.941 by $0.099.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is $0.89.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 50,786,118 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.04 in its last earnings report, beating expectations of $0.941. Following the earnings report the stock price went up 1.297%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Among the largest hedge funds holding Haemonetics Corp.’s share is Royce & Associates LLC. It holds Haemonetics Corp.’s shares valued at 83M.
---
Haemonetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$105.75 (24.59% Upside)
$105.75 (24.59% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 127.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.71%
12-Months-Change
Fundamentals
Return on Equity
14.72%
Trailing 12-Months
Asset Growth
17.16%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.
---
HAE Earnings Call
Q3 2024
0:00 / 0:00
---
HAE Stock 12 Months Forecast
Average Price Target
$105.75
▲(24.59% Upside)
Technical Analysis
Best Analysts Covering HAE
1 Year
1 Year Success Rate
27/45 ratings generated profit
1 Year Average Return
+9.37%
reiterated a buy rating 2 months ago
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +9.37% per trade.
---